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ORIGINAL ARTICLE
Molecular and Clinicopathologic Heterogeneity of
Intracranial Tumors Mimicking Extraskeletal Myxoid
Chondrosarcoma
Julia Velz, MD, Abbas Agaimy, MD, Karl Frontzek, MD, Marian Christoph Neidert, MD,
Oliver Bozinov, MD, Ulrich Wagner, PhD, Christine Fritz, MSc, Roland Coras, MD,
Silvia Hofer, MD, Beata Bode-Lesniewska, MD, and Elisabeth Rushing, MD
Abstract
Primary intracranial neoplasms with features of extraskeletal
myxoid chondrosarcomas (EMC) are extremely rare and poorly
characterized tumors with only 12 cases described, the majority
lacking molecular confirmation. There is an urgent need for the inte-
gration of molecular studies for correct subclassification of these
tumors in order to predict clinical behavior, guide therapeutic
decision-making, and provide novel targets for therapy. Clinical and
pathologic data of 3 intracranial EMC-like myxoid neoplasms were
retrospectively reviewed. In 2/3 cases, immunohistochemistry
showed loss of nuclear SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily B member 1
(SMARCB1; integrase interactor 1 [INI1]) staining accompanied by
monosomy of chromosome 22q (fluorescence in situ hybridization
[FISH]). These 2 cases had no evidence of any fusion products by
next generation sequencing (NGS). The third case had intact
SMARCB1 expression and showed instead a rearrangement of the
EWSR1 gene detected by FISH, with an EWSR1-CREB1 gene fusion
on NGS. None of the cases showed rearrangement of the NR4A3
gene, neither by FISH nor by NGS. This small case series highlights
the molecular heterogeneity of intracranial neoplasms in the mor-
phologic spectrum of EMC. Distinct molecular alterations found in
tumors with morphologic features of EMC encompass SMARC-
B1(INI1) loss and EWSR1-CREB gene fusions. None of the cases
showed rearrangements of NR4A3 genes, suggesting they are distinct
from conventional EMC.
Key Words: Cartilaginous tumors, EWSR1, Intracranial extraskeletal
myxoid chondrosarcoma, SMARCB1 (INI1) loss.
INTRODUCTION
Recent advances in understanding the molecular back-
ground of mesenchymal neoplasms with evident or presumed
cartilaginous differentiation have led to extensive revision in
the classification. Historically, conventional, mesenchymal
and extraskeletal myxoid chondrosarcomas (EMC) have been
distinguished, with the conventional type being by far the
most common in both extracranial and cranial locations (1–3).
Intracranial cartilaginous tumors are rare, accounting for
<0.16% of all space-occupying brain tumors (4). The distribu-
tion of reported primary intracranial EMC-like neoplasms is
highly variable with lesions described in the pineal region,
frontal, temporal and parietal cortex, the falx, fourth ventricle
and the cerebellum (1, 5–13) (Table 1). However, the lack of
rigorous diagnostic criteria and the use of ambiguous termi-
nology have resulted in misclassification of cartilaginous
tumors in the past. For example, higher-grade conventional
chondrosarcoma of the skull containing a myxoid rather than
hyaline extracellular matrix (as is typical for low-grade con-
ventional chondrosarcoma) has been misclassified as “myxoid
chondrosarcoma”. Nosologic imprecision has led to confusion
with the histogenetically ambiguous but biologically distinct
entity of EMC, which has eroded the significance of previous
publications on this entity.
The current classification of mesenchymal tumors con-
tinues to evolve by incorporating more genetic information in
the diagnostic algorithm (14). Among the chondrogenic
tumors, conventional chondrosarcomas are characterized by
mutations in the IDH1/IDH2 genes, while mesenchymal chon-
drosarcomas and EMC belong to translocation associated sar-
comas involving the HEY1-NCOA2 and NR4A3 genes,
respectively (15).
None of the older publications contains information on
the genetic background of the reported tumors. In fact, only
very few recent papers address the underlying genetic mecha-
nisms of intracranial myxoid chondrogenic neoplasms, which
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microscopically correspond to the rather broad category of
EMC. Interestingly, Kao and Bale report translocations of the
EWSR1-CREB-family of genes translocations in 7 cases (4
cases EWSR1-CREB1, 2 cases EWSR1-CREM, and 1 case
EWSR1-ATF1) (16, 17) (Table 2). These translocations have
previously been reported in rare, mostly mesenchymal tumors
of divergent clinical potential and heterogeneous histogenetic
origin/line of differentiation. These entities encompass clear
cell sarcoma, clear cell sarcoma-like tumor of the gastrointes-
tinal tract (CCSLTGT) (synonym: malignant gastrointestinal
neuroectodermal tumor), angiomatoid fibrous histiocytoma
(AFH), and primary pulmonary myxoid sarcoma (PPMS) in
addition to epithelial neoplasms such as hyalinizing clear cell
carcinoma (HCCC) of the salivary gland and sclerosing clear
cell odontogenic carcinoma (18). It seems that there is a pecu-
liar subgroup of intracranial myxoid tumors, morphologically
mimicking EMC, which harbors this translocation as well,
broadening the spectrum of tumors linked to the EWSR1-
CREB-family of translocation genes. Integrase interactor 1
(INI1) status was also investigated because rare extraskeletal
tumors resembling EMC show loss of this marker (19).
In order to further elucidate the molecular background
of the intracranial myxoid neoplasms previously classified as
EMC, we studied 3 such tumors, collecting available clinical
information and applying conventional, immunohistochemical
and molecular (fluorescence in situ hybridization [FISH], next
generation sequencing [NGS]) methods.
MATERIALS ANDMETHODS
All procedures performed in studies involving human
participants were in accordance with the ethical standards of
the institutional and/or national research committee and with
the 1964 Helsinki declaration and its later amendments or
comparable ethical standards.
Three cases of “intracranial EMC” were retrieved from
the pathology files of our respective institutions. Hematoxylin
and eosin (H&E) sections and immunohistochemical stains
performed at the time of diagnosis were reviewed. Clinical
and follow-up data were obtained from the clinical database.
FISH and NGS technology were used to investigate molecular
alterations.
This study was approved by our institutional review
board (the Cantonal Ethics Committee; KEK_ZH 2013-
0430).
Histology and Immunohistochemistry
Tumor tissue samples were fixed in buffered 4% forma-
lin and embedded in paraffin. The 2-lm-thick sections were
stained with H&E according to standard procedures. Immuno-
histochemistry using the SWI/SNF-related matrix-associated
actin-dependent regulator of chromatin subfamily B member
1 (SMARCB1) (INI1) antibodies (clone MRQ-27, Zytomed
[dilution 1:50] and clone BAF47, BD Biosciences [dilution
1:300]), (Franklin Lakes, NJ) was performed on 2-lm-thick
paraffin sections, using the Ventana Benchmark XT
TABLE 1. Cases of Intracranial Extraskeletal Myxoid Chondrosarcoma Described in the Literature
Author Age/Sex Location/Attachment Treatment Outcome
Scott (1976) (5) 39/M 4th ventricle, choroid plexus Surgery 13 days, died (ventriculitis)
Smith (1981) (12) 12/M Left cerebellar hemisphere and foramen Surgery 13 months, alive, free of disease
magnum (dura)
Salcman (1992) (28) 28/F Left parafalcine and dura of falx Surgery and brachytherapy 20 months, alive, local recurrence
Sato (1993) (29) 43/F Pineal gland and dura Surgery, radiotherapy
and chemotherapy
3 years, died (tumor progress)
Gonzalez-Lois (2002) (1) 17/F Fronto-temporal (dura and hemisphere) Surgery and radiotherapy 19 months, alive, local recurrence
Chaskis (2002) (6) 69/M Parietal, Cortex left Surgery and radiotherapy 1 months died with septic shock
d/t diverticulitis
Im (2003) (7) 43/M Parietal, Cortex left Surgery and radiotherapy 3 years alive, no recurrence
Sorimachi (2008) (13) 37/F Pineal gland (no dura or plexus
choroideus attachment)
1st surgery 1st: 13 months recurrence
2nd surgery 2nd: 7 months alive, no tumor
recurrence
OBrien (2008) (8) 26/F Left cerebellopontine angle 1st surgery 1 year after surgery no evidence
of any tumor enlargement2nd surgery
proton therapy
Arpino (2011) (30) 54/F Sellar/left parasellar mass Surgery ND
Park (2012) (9) 21/F Left lateral ventricle/choroid plexus Surgery and radiotherapy 6 months, alive
Dulou (2012) (10) 70/m Left frontal Lobe Radiotherapy, surgery
and chemotherapy
10 months, died
Lee (2015) (11) 67/m Left temporal Lobe Radiotherapy and surgery ND
Described Case No.1 58/F Pineal Gland Surgery and Radiotherapy ND
Described Case No. 2 30/F Left cerebellopontine angle Surgery and radiotherapy 4 months, alive
Described Case No. 3 17/M Left cerebellopontine angle Surgery and radiotherapy 3 years alive; tumor recurrence
F, female; M, male; ND, no data available.
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automated staining system (Ventana Medical Systems,
Tucson, AZ).
Fluorescence In Situ Hybridization
The FISH studies were performed on formalin-fixed,
paraffin-embedded, 2-lm-thick tissue sections. Dual color
break-apart FISH detecting translocations involving the
EWSR1 (22q11) and NR4A3 (9q22.33-q31.1) genes was per-
formed using commercially available probes (Vysis, Abbott
AG, Baar, Switzerland and ZytoVision GmbH, Bremerhaven,
Germany, respectively). Fluorescence staining was visualized
with an Olympus BX61 microscope (Olympus, Volketswil,
Switzerland) equipped with DAPI, SpectrumGreen and Spec-
trumOrange filters. Images were acquired with a CCD camera
and processed with AnalySIS imaging software (Soft Imag-
ining System, Munster, Germany). For the assessment of
EWSR1 and NR4A3 gene rearrangements, at least 50 nono-
verlapping tumor nuclei were analyzed. If the sample con-
tained at least 25% of split red and green signals, the tumor
was regarded as translocation-positive. The signal was con-
sidered as split, when red and green fluorescent spots were
separated by at least twice the distance occupied by a single
probe.
To detect copy number alterations of the SMARCB1
(INI1) gene locus, FISH was performed using the ZytoLight
SPEC SMARCB1/22q12 Dual Color Probe, which is a mix-
ture of a green fluorochrome direct labeled SPEC SMARCB1
probe hybridizing to the human SMARCB1 gene in the chro-
mosomal region 22q11.23 and an orange fluorochrome direct
labeled SPEC 22q12 probe as supplied by the manufacturer
(ZytoVision GmbH). Absence of 1 or both of SMARCB1 green
signals but intact 22q12 orange signals is reported as monoal-
lelic and biallelic deletion of SMARCB1, respectively. Ab-
sence of 1 orange and 1 green signal is reported as monosomy
22q or at least part of it spanning both SMARCB1 gene locus
and 22q region.
Next Generation Sequencing
Ribonucleic acid (RNA) was extracted using theMaxwell
16 LEV RNA FFPE Purification Kit (Promega Corporation,
Madison, WI) according to the manufacturer’s instructions.
Libraries were prepared using Anchored Multiplex PCR with
the commercially available Archer FusionPlex Sarcoma Panel
(ArcherDx, Boulder, CO), which simultaneously identifies
fusions of 26 genes associated with soft tissue sarcomas. The
RNA input was as follows: Case 1: 250 ng, Case 2: 80 ng, and
Case 3: 250 ng. Briefly, complementary DNA was synthesized
using random primers. After synthesis of the first strand, 1 ll
of the reaction was run in a PreSeq assay (qPCR) to ensure
sufficient RNA quality. Synthesis of the second cDNA strand
was followed by an end repair step and libraries were cleaned
using Agencourt AMPure XP beads (Beckman Coulter, Brea,
CA). Samples were adenylated with a first ligation step and
cleaned again with AMPure beads. In a second ligation step a
molecular barcode adapter was incorporated to the libraries,
which contains a random 8-mer used to differentiate individ-
ual nucleic acid molecules in the samples before any amplifi-
cation occurs. After cleanup with ligation cleanup beads
(ArcherDx), libraries were amplified in a first PCR reaction
using gene-specific primers (GSP1), cleaned with AMPure
beads, followed by a second PCR reaction with gene-specific
primers (GSP2) to increase amplicon specificity perform tar-
get enrichment and add an index for multiplexing. Libraries
were then quantified using qPCR (KAPA Biosystems, South
San Francisco, CA), normalized and processed for sequencing.
Samples were sequenced on the MiSeq platform (Illumina,
San Diego, CA) with a minimum of 2 million reads per
sample.
Sequencing Data Analysis
The resulting fast-files were analyzed using the stan-
dard RNA fusion workflow as implemented in the Archer
Analysis Suite 5.1.3. Briefly, after adapter trimming, reads
were deduplicated using the random 8-mer molecular bar-
code. Reads were then mapped to control and target regions
and finally to the human genome (hg19). Chimeric reads
aligning to 2 separate genes with little or no overlap were
considered fusion candidates. Reads with identical break-
points in the fused genes were used to establish a consensus
sequence. Subsequently, reads were then mapped back to
this consensus.
TABLE 2. Recently Described Intracranial Myxoid Chondrogenic Neoplasms (iMCN) With Genetic Information
Author Age/Sex Location/Attachment Immunohistochemistry Fusion Type
EMA Desmin
Kao et al (16) 15/F Meninges Fþ Dþ ESWR1-CREM
Kao et al (16) 23/F Meninges (occipital) Fþ Dþ ESWR1-CREB1
Kao et al (16) 20/M Brain (frontal) Fþ Fþ ESWR1-CREB1
Kao et al (16) 12/M Brain (frontal) Fþ Fþ ESWR1-ATF1
Bale et al (17) 12/M Posterior fossa/cerebellar, abutting dura Fþ Dþ ESWR1-CREB1
Bale et al (17) 14/M Intraventricular (left lateral) Fþ Dþ ESWR1-CREB1
Bale et al (17) 18/M Midline/right frontal (falx area), surrounded
by a thin rim of brain parenchyma
Fþ Dþ ESWR1-CREM
F, female; M, male; Fþ, focal-positive; Dþ, diffuse-positive.
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RESULTS
Clinical Features
Case 1 (Fig. 1). A 58-year-old female patient was re-
ferred to the Neurosurgery Department of the University Hos-
pital of Zurich after an episode of vertigo and visual
disturbances accompanied by a change in her usual headache
pattern. MRI revealed a space-occupying lesion in the pineal
region. The patient underwent a midline suboccipital osteo-
plastic craniotomy with resection of the tumor. Histopathologic
examination revealed an intracranial neoplasm consistent with
EMC. The perioperative period was uneventful. Postoperative
resection control (MRI) showed radiologic evidence of a resid-
ual mass and the patient was referred for stereotactic irradiation
of the residual tumor. A whole-body CT and/or PET to exclude
further tumor sites was not performed. The patient was postop-
eratively lost to follow-up.
Case 2 (Fig. 2). A 30-year-old woman was referred to the
neurosurgery department of an external hospital with a newly di-
agnosed mass occupying the left cerebellopontine angle with
extrameatal and intrameatal components and signs of brainstem
compression. The patient had presented with new onset of ver-
tigo of several weeks duration. ENT examination revealed slight
hearing loss and vestibular dysfunction on the left side. The
suspected initial diagnosis was vestibular schwannoma. The le-
sion was removed using microsurgical techniques via
suboccipito-lateral trepanation. Intraoperatively, the cochlear
nerve was seen attached to and traversing the entire mass. The
part of the lesion associated with the fascial nerve could not be re-
moved completely. Postoperative PET-CT showed no evidence
of metastasis or another extracranial primary tumor. Adjuvant ra-
diotherapy was given at a total dose of 63Gy. At last follow-up,
4months after surgery, the patient was alive and without evi-
dence of disease after completion of the radiation therapy.
Case 3 (Fig. 3). A 17-year-old boy was referred to the
Children’s Health Centre of an external hospital with a newly
diagnosed lesion with perifocal edema occupying the left cere-
bellopontine angle in December 2014 (Fig. 4). The patient,
who suffered from migraine, noted a change of his usual head-
ache pattern over several weeks in association with nausea.
Upon admission, he showed lower cranial nerve deficits (VII,
IX, X) without explicit cerebellar signs. A left retromastoid
suboccipital craniotomy was performed with removal of the
tumor within the visible boundaries. The perioperative period
was uneventful. The postoperative resection control (MRI)
showed no radiologic signs of any residual mass (Fig. 4). The
histopathology was reevaluated several times, including at
multiple international brain tumor reference centers. Initially,
FIGURE 1. (Case 1) Tumor of the pineal region of a 58-year-old woman. (A) H&E stain, original magnification: 200. (B) Loss of
nuclear expression of INI1 protein in the tumor cells in contrast to non-neoplastic nuclei of the endothelial cells (arrows), original
magnification: 200). (C, D) Interphase FISH demonstrates lack of rearrangement of the EWSR1 and NR4A3 genes, respectively.
The tumor nuclei contain exclusively fused green and orange signals. (E) FISH demonstrates monosomy for the 22q gene locus
with single INI1/SMARCB1 signal and single centromere signal.
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FIGURE 2. (Case 2) Intracranial tumor in the left cerebellopontine angle of the 30-year-old woman. (A) H&E stain, original
magnification: 200. (B) Loss of nuclear expression of INI1 protein in the tumor cells in contrast to non-neoplastic nuclei of the
blood vessels (arrow), original magnification: 200. (C) FISH demonstrates monosomy for the INI1/SMARCB1 gene/22q: The
nuclei of the tumor cell contain one signal each. The FISH showed no rearrangement of the EWSR1 and N4RA3 genes (not
shown).
FIGURE 3. (Case 3) Infratentorial tumor of the 17-year-old boy. (A) H&E stain, original magnification: 200. (B) Retained
nuclear expression of INI1 protein, original magnification: 200. (C) Interphase FISH demonstrating the rearrangement of the
EWSR1 gene. One fused gene signal (arrowhead) is accompanied by split green and orange signals (arrows) in the tumor nuclei.
(D) Interphase FISH demonstrates the lack of rearrangement of the NR4A3 gene. The tumor nuclei contain exclusively fused
green and orange signals. FISH analysis shows normal disomic pattern for the INI1/SMARCB1 gene (not shown).
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a meningioma or schwannoma was discussed. Radiologic
follow-up examination was performed 4 and 8months after
surgery, which showed a recurrence of the infratentorial lesion.
In September 2015, the patient was referred to another external
hospital, where recraniotomy with a suboccipital approach was
undertaken to remove recurrent tumor from the left cerebello-
pontine angle. Again, there was uncertainty regarding the his-
topathologic diagnosis. Follow-up imaging 3 and 6months
after the second surgery did not show any evidence of recurrent
tumor. In March 2016, the patient noted increased severity of
headaches and vertigo. cMRI in August 2016 showed 6 new
extracerebral nodules in the basal cistern (including 1 lesion in
the region of previous surgery). In September 2016, the histo-
logic samples were sent in consultation to the Neuropathology
Department of the University of Zu¨rich, where histopathologic
examination revealed intracranial EMC. Rearrangement of the
EWSR1 gene was demonstrated by FISH analysis (Fig. 3C)
(NR4A3 gene FISH and NGS were not available at that time).
At last follow-up, 3 years after initial diagnosis, the patient was
still alive and MRI showed recurrence of the tumor.
Pathologic Findings
Microscopic Examination
Case 1 (Fig. 1A). The tumor tissue consisted of variably
dense cords of small to middle sized oval to spindled cells
embedded in a prominent myxoid matrix. Focal areas with dense
fibrotic material or more pronounced chondrohyaline matrix
were observed. Mitotic figures were rare. No necrosis was found.
Case 2 (Fig. 2A). Histologic examination showed mod-
erately atypical plump elongated to rounded epithelioid cells
with vesicular chromatin. There were occasional small incon-
spicuous nucleoli and pale-eosinophilic cytoplasm with fre-
quent plasmacytoid cell features resulting from paranuclear
condensation of the cytoplasm. Foci of spindled and binucle-
ated cells were seen as well. The neoplastic cells were ar-
ranged into reticular cords and trabeculae within a prominent
myxoid fibrovascular stroma with occasional chondromyxoid
features. Mitotic activity was in the range of 4 mitoses/10
high-power fields. The tumor was closely associated with
nerve fibers, with areas of frank intraneural invasion.
Case 3 (Fig. 3A). Microscopic examination revealed
cords and communicating reticular/pseudoacinar aggregates
of monomorphic, round to oval tumor cells, embedded in a
myxoid stroma, and imparting a lacelike appearance. Mitotic
figures or necrosis was not observed; however, occasional ap-
optotic bodies were seen.
Immunohistochemistry
Case 1. Immunohistochemistry showed negativity for
AE1/AE3, EMA, S100, CD34, p63, MUC4, CD117, SMA,
FIGURE 4. (Case 3) Soft tissue window of preoperative axial CT scan (A). (B) Axial section of preoperative T2-weighted MRI shows a
newly diagnosed mass with perifocal edema occupying the left cerebellopontine angle. Axial (C) and coronal (D) sections of
preoperative T1-weighted and contrast-enhanced MRI (December 2014). Axial and contrast-enhanced section of T1-weighted (E)
and axial T2-weighted MRI (F) in August 2015 reveal recurrence of the infratentorial lesion; recraniotomy was performed to remove
the recurrent tumor in September 2015. During follow-up in September 2016, axial sections of T1-weighted and contrast-enhanced
MRI (G, H) displayed 6 new extracerebral nodules in the basal cistern (only 2 lesion sites are shown, G, H).
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desmin, brachyury, and synaptophysin. There was loss of nu-
clear expression of SMARCB1 (Fig. 1B) in the tumor cells in
contrast to non-neoplastic stromal or vascular cells in the
background. The proliferation index (Ki67) was<5%.
Case 2. Immunohistochemistry showed consistent ex-
pression of EMA and smooth muscle actin. In addition, there
was weak to moderate nuclear reactivity for ERG as well as
scattered p63-positive cells. A panel of immunohistochemical
stains was performed including S100, SOX10, desmin,
MUC4, CD34, STAT6, SSTR2A, AE1/AE3, CD31, CD30,
D2-40, ALK, Brachyury, and CD117; all were negative. The
neoplastic cells showed complete loss of SMARCB1/INI1
(Fig. 2B), with retained expression in normal stromal cells.
The proliferation fraction (Ki67) was 10%.
Case 3. The tumor cells were negative for pancytokera-
tin, S100 protein and EMA, claudin-1, MUC4, and synapto-
physin. Nuclear expression of INI1 protein was retained in the
tumor cell nuclei (Fig. 3B). The Ki67 proliferation index was
10%.
FISH Analysis
The results of the FISH analyses of all cases are sum-
marized in Table 3. The FISH analysis of the EWSR1 gene
showed no rearrangement in the tumor of the Patients 1 and
2, while the FISH probe signals were split in the tumor of
Patient 3, indicating a translocation involving this gene
(Figs. 1C, 3C). None of the tumors showed rearrangement of
the NR4A3 gene in the FISH analysis (Figs. 1D, 3D).
The SMARCB1/22q12 FISH analysis showed heterozy-
gous deletion in the tumor cell nuclei of Patients 1 and 2 fre-
quently associated with loss of the 22q centromere signals
indicating monosomy at 22q locus, while Patient 3 had 2
SMARCB1 gene signals per nucleus (Figs. 1E, 2C).
Next Generation Sequencing
NGS using the Archer FusionPlex Sarcoma Panel did
not detect any gene fusions of the 26 genes studied in the tu-
mor tissue of the Patients 1 and 2. In the tumor tissue of the Pa-
tient 3 an EWSR1-CREB1 gene fusion was identified.
DISCUSSION
Intracranial EMC is exceptionally rare with only ap-
proximately a dozen cases reported since its first description
in 1972 (3, 13) (Table 1). Due to its rarity, the clinicopatho-
logic and molecular characteristics of this neoplasm have not
been sufficiently analyzed. High rates of recurrence in patients
with intracranial EMC undergoing radical excision and adju-
vant radiotherapy have been described in previous reports
(1, 13). Treatment standard consists of radical excision to
achieve total removal of the tumor (1, 2, 8). Adjuvant thera-
pies, including radiotherapy and proton beam treatment, have
been found to improve patient outcomes for this rare cancer
(Table 1). Nevertheless, there is an urgent need to identify mo-
lecular markers that can reliably predict clinical behavior,
guide therapeutic decision-making and that can serve as novel
targets for therapy. The field of sarcoma classification has en-
tered a new era with the introduction of paradigms based on
molecular alterations. Approximately one-third of all soft tis-
sue tumors harbor recurrent (mainly balanced) chromosomal
translocations, usually encoding aberrant chimeric transcrip-
tion factors. Pathognomonic chromosomal translocations may
even define specific sarcoma entities and can be used as highly
specific prognostic markers in the appropriate clinical and
pathologic context. However, it has become apparent that
some gene fusions are not necessarily specific for a given his-
tologic subtype but are shared among various sarcoma (or
even carcinoma) types otherwise unrelated clinically or immu-
nophenotypically. EWSR1, encoding the RNA-binding protein
ESWR1, a member of the TET family of transcription fac-
tors, is a prototypical “promiscuous gene” with a propensity
for fusing with a host of different genes. In fact, rearrange-
ment of ESWR1 have been found in a variety of mesenchy-
mal and other neoplasms including the Ewing family of
tumors (18).
ESWR1-NR4AR Fusion
The rearrangement of the NR4A3 gene is, according to
the current WHO classification, the defining molecular fea-
ture of EMC (14). In approximately two-thirds of cases of
EMC, a chromosomal reciprocal translocation of t(9;
22)(q22; q12) has been identified, which corresponds to the
EWSR1/NR4A3 gene fusion (20). NR4A3 gene fusions to
other gene partners including TATA binding protein-associ-
ated factor 15 (TAF15), transcription factor 12 (TCF12),
and TRK-fused gene (TFG) have been described in a smaller
proportion of cases and correlate with rhabdoid phenotype,
high-grade morphology and a more aggressive outcome in
EMC (20). None of the cases described in the current study
showed the classical rearrangement of the EMC, involving
the NR4A3 gene.
TABLE 3. Immunohistochemical and Molecular Analyses
Case No. Age/Sex INI1 IHC INI1 FISH EWS FISH NR4A3 FISH FusionPlex Sarcoma Panel (Archer)
1 58/F Loss Monosomy Negative Negative Negative
2 30/F Loss Monosomy Negative Negative Negative
3 17/M Nuclear Disomy Positive Negative EWSR1-CREB1
F, female; M, male.
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ESWR1 Fusion With CREB Family Transcription
Factors
Gene fusions of EWSR1 with members of the cAMP re-
sponse element binding protein (CREB), including CREB1 and
ATF1, have been identified in 5 histopathologically diverse
neoplasms: AFH, conventional clear cell sarcoma, CCSLTGT,
HCCC of the salivary gland, and PPMS (18, 21–24).
EWSR1-ATF1 and/or EWSR1-CREB1 are examples of
gene fusions that are not restricted to a specific histomorpho-
logic pattern. The histologic overlap and nonspecific immuno-
profile of different tumor types have led to the discussion of a
single pathologic entity characterized by morphologic diver-
sity and shared genetics, rather than distinct tumor types with
overlapping gene fusions. Of note, PPMS show some histo-
logic overlap and similar genetic features with AFH, despite
desmin negativity and the lack of lymphoplasmacytic cuffing,
raising the possibility of a pulmonary myxoid variant of AFH.
Kao et al reported of a series of 5 myxoid mesenchymal
neoplasms with a remarkable predilection for the meninges
and brain in young patients that were characterized by similar
morphology and immunoprofile. Their genetic hallmark was
the presence of EWSR1 fusions with members of the CREB
gene family (CREM, CREB1, and ATF1) (Table 2).
SMARCB1 (INI1)-Deficient Neoplasia
SMARCB1, which is also named INI1, is 1 of the core
subunit proteins in the SWI/SNF (SWItch/Sucrose Non-Fer-
mentable) ATP-dependent chromatin remodeling complex.
SMARCB1/INI1 plays an important role in several pathways
related to tumor proliferation and progression (WNT, Sonic
hedgehog, p16-RB pathway and Polycomb pathway). The
clinicopathologic spectrum of intracranial neoplasms display-
ing consistent loss of nuclear SMARCB1 (INI1) expression
has been steadily expanding to encompass not only the atypi-
cal teratoid rhabdoid tumor, but also pediatric chordomas, sy-
novial sarcoma, and the so-called cribriform neuroepithelial
tumor (25–27). In our case series, 2 patients (Cases 1 and 2)
showed loss of INI1 expression. Whether INI1 deficient intra-
cranial tumors of the type described in this study comprise a
separate entity remains to be established.
In the current series, we demonstrated that neoplasms in
the clinicopathologic and morphologic spectrum of intracra-
nial EMC are heterogeneous at the molecular level. Notably,
none of the 3 cases harbored a NR4A3 gene fusion, highlight-
ing their molecular distinctness from EMC of soft tissues and
other extracranial sites. Instead, 1 tumor demonstrated
EWSR1-CREB1 gene translocations. The latter aberration has
been reported in a variety of mesenchymal and rarely also epi-
thelial neoplasms. In particular, primary pulmonary myxoid
sarcoma which is well known to be closely related to EMC
morphologically was found to harbor these same EWSR1-
CREB1 gene fusions in the vast majority of cases (18, 28). In-
deed, some reports on EMC primary in the lung have been
considered examples of primary pulmonary myxoid sarcoma.
In a recent report, Agaimy et al demonstrated loss of
SMARCB1 in a case of primary pulmonary myxoid sarcoma
that lacked gene fusions in the EWSR1, FUS and NR4A3 gene
loci, suggesting SMARCB1 deficiency as an alternative
molecular event driving some neoplasms in the morphologic
spectrum of primary pulmonary myxoid sarcoma (29). In the
current study, we observed same phenomenon where 2 of our
3 cases of intracranial EMC lacked these characteristic gene
fusions (both by FISH and NGS) and instead displayed com-
plete loss of SMARCB1 protein by immunohistochemistry as
a consequence of monoallelic SMRACB1 gene locus deletion
demonstrable by FISH.
Conclusion
Comprehensive analysis of the clinicopathologic fea-
tures and molecular alterations of intracranial EMC-like neo-
plasms underscore the genetic variability and molecular
heterogeneity of neoplasms in the clinicopathologic spectrum
of intracranial EMC. At least in our small series, intracranial
EMC seems to be distinctive from conventional (soft tissue)
EMC at extracranial sites. Analogous to similar pulmonary
lesions, the noncommitted term “primary intracranial myxoid
sarcoma” might be more convenient for this rare entity. Mo-
lecular suptyping of these rare diseases may be relevant for fu-
ture management of affected patients and may help to
optimize therapeutic decisions.
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